Insider Buying: Elanco Animal Health (NYSE:ELAN) CEO Acquires 4,971 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CEO Jeffrey Simmons purchased 4,971 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, with a total value of $99,867.39. Following the completion of the acquisition, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Elanco Animal Health Stock Down 0.8%

NYSE ELAN traded down $0.16 during trading on Tuesday, reaching $19.78. 7,919,678 shares of the company’s stock were exchanged, compared to its average volume of 5,317,265. The stock has a market cap of $9.88 billion, a P/E ratio of -39.55, a price-to-earnings-growth ratio of 2.14 and a beta of 1.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The company has a 50 day moving average price of $23.23 and a two-hundred day moving average price of $23.33. Elanco Animal Health Incorporated has a 1 year low of $12.40 and a 1 year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.Elanco Animal Health’s revenue for the quarter was up 14.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.37 EPS. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, equities research analysts anticipate that Elanco Animal Health Incorporated will post 1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ELAN shares. Leerink Partners lifted their price target on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a report on Tuesday, February 24th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Citigroup boosted their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, KeyCorp boosted their target price on Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $28.20.

Hedge Funds Weigh In On Elanco Animal Health

Several institutional investors have recently added to or reduced their stakes in ELAN. UBS Group AG increased its position in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after acquiring an additional 5,961,457 shares during the period. Sei Investments Co. increased its position in Elanco Animal Health by 737.5% in the 1st quarter. Sei Investments Co. now owns 5,650,393 shares of the company’s stock valued at $135,214,000 after acquiring an additional 4,975,721 shares during the period. T. Rowe Price Investment Management Inc. increased its position in Elanco Animal Health by 11.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock valued at $797,197,000 after acquiring an additional 3,717,404 shares during the period. Invesco Ltd. increased its position in Elanco Animal Health by 336.0% in the 4th quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock valued at $108,376,000 after acquiring an additional 3,690,735 shares during the period. Finally, Allspring Global Investments Holdings LLC acquired a new position in Elanco Animal Health in the 1st quarter valued at about $66,390,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.